<DOC>
	<DOCNO>NCT01283373</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label , dose-escalation study DSTP3086S administer single agent intravenous ( IV ) infusion patient metastatic Castration-Resistant Prostate Cancer ( CRPC ) .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Escalating Doses DSTP3086S Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy least 12 week Histologic documentation adenocarcinoma prostate Surgical castration ongoing use gonadotropinreleasing hormone agonist confirm castrate level testosterone Metastatic progressive CRPC define progressive disease despite surgical castration ongoing use gonadotropinreleasing hormone agonist confirm castrate level testosterone For patient doseexpansion cohort study , two prior line cytotoxic chemotherapy metastatic set Evaluable measurable disease Documented willingness use effective mean contraception Antitumor therapy , include chemotherapy , biologic , experimental , hormonal therapy , radiotherapy within 4 week prior Day 1 , follow exception : maintenance hormonal therapy metastatic prostate cancer palliative radiation bone metastasis within 2 week prior Day 1 Major surgical procedure within 4 week prior Day 1 Known active bacterial , viral , fungal , mycobacterial , infection ( include HIV atypical mycobacterial disease , exclude fungal infection nail bed ) Ongoing corticosteroid use &gt; 10 mg daily prednisone equivalent Symptomatic hypercalcemia require continue use bisphosphonate therapy . Patients receive bisphosphonate therapy specifically prevent skeletal event history clinically significant hypercalcemia eligible . History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Untreated active central nervous system ( CNS ) metastasis . Patients history treat CNS metastasis eligible , provide meet follow criterion : evaluable measurable disease outside CNS , radiographic demonstration improvement upon completion CNSdirected therapy evidence interim progression completion CNSdirected therapy screen radiographic study , screen CNS radiographic study &gt; /= 8 week since completion radiotherapy &gt; /= 4 week since discontinuation corticosteroid anticonvulsant Dose expansion cohort ( B ) : prior chemotherapy allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>